search
Back to results

Tailored Radiofrequency Ablation of Uterine Myomas

Primary Purpose

Uterine Fibroids

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
RADIOFREQUENCY ABLATION OF UTERINE MYOMAS
Sponsored by
International Evangelical Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uterine Fibroids

Eligibility Criteria

30 Years - 62 Years (Adult)FemaleAccepts Healthy Volunteers

"Inclusion Criteria":

  • women who had symptomatic myomas with diameters ranging between 1.2 and 7.7 cm. - patients who had declined hysterectomy or laparoscopic myomectomy
  • submucosal fibroids with intramural extension ≥50%
  • intramural fibroids (FIGO G3 / G4 types)
  • subserosal fibroids (FIGO G5 / G6 types)

"Exclusion Criteria":

  • Women with intracavitary (FIGO G0 / G1 types) or subserosal-pedunculated fibroids / (FIGO G7 types)
  • genital malignancy
  • cervical dysplasias
  • pelvic infection / adhesions
  • severe systemic diseases
  • pregnancy
  • deeply infiltrating endometriosis
  • patients who took gonadotropin-releasing hormone therapy or acetate ulipristal within 6 months

Sites / Locations

  • International Evangelical Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Radiofrequency myolysis of uterine fibroids

Arm Description

54 premenopausal participants with symptomatic uterine myomas

Outcomes

Primary Outcome Measures

Myoma volumes after radiofrequency myolysis (RFM)
The outcomes evaluated after RFM were myoma volumes (cubic centimeters)
Myoma diameters after radiofrequency myolysis (RFM)
The outcomes evaluated after RFM were myoma diameters (centimeters)
Uterine Fibroid Symptom and Quality of Life (UFS-QOL) score after radiofrequency myolysis (RFM)
Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire with scores ranging from 0 to 100, were higher QOL scores mean a better health-related QOL 1 and a 10-point scale used for each reported symptom.

Secondary Outcome Measures

Surgical time of radiofrequency myolysis (RFM)
The surgical time (minutes) for each different type of surgical access
Surgical time of radiofrequency myolysis (RFM) assisted by new technologies
The reduction of surgical time (minutes) with the use of a virtual global positioning system (GPS) track system or a contrast-enhanced ultrasound during the ablation
Pre-intervention biopsy associated to radiofrequency myolysis (RFM)
The number of biopsies for treated fibroma

Full Information

First Posted
July 21, 2019
Last Updated
September 16, 2019
Sponsor
International Evangelical Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04091529
Brief Title
Tailored Radiofrequency Ablation of Uterine Myomas
Official Title
A Prospective Study on Radiofrequency Ablation of Uterine Fibroids (Myolysis) Under Ultrasound and Endoscopic Guidance, in Single or Combined Approach
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
March 1, 2019 (Actual)
Study Completion Date
March 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
International Evangelical Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To perform the use of radiofrequency myolysis (RFM) for the treatment of intra-uterine fibroids through less invasive access by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy
Detailed Description
Given that the RF ablation of solid tumors of the liver and other organs is successfully used as a usual approach, the investigators have decided to transfer this technology to an original treatment of uterine fibroids. The access to each individual fibroid was determined considering passage of the needle towards its centre through only compromised tissue and by the shortest possible route by combining trans-vaginal ultrasound, hysteroscopy and laparoscopy. To optimize radiofrequency myolysis, in fact, the investigators decided to improve the procedure by inserting three innovative elements: application of a virtual needle tracking system to follow the RF electrode during the ablation session, real-time monitoring of RF ablation by contrast-enhanced ultrasound and systematic biopsy of the lesions before electro-coagulation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroids

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Radiofrequency myolysis of uterine fibroids
Arm Type
Experimental
Arm Description
54 premenopausal participants with symptomatic uterine myomas
Intervention Type
Device
Intervention Name(s)
RADIOFREQUENCY ABLATION OF UTERINE MYOMAS
Other Intervention Name(s)
Radiofrequency myolysis (RFM), RF lesion generator for tissue ablation during surgical procedures. Sterile single-use RF coagulation monopolar electrode.
Intervention Description
The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
Primary Outcome Measure Information:
Title
Myoma volumes after radiofrequency myolysis (RFM)
Description
The outcomes evaluated after RFM were myoma volumes (cubic centimeters)
Time Frame
12 months
Title
Myoma diameters after radiofrequency myolysis (RFM)
Description
The outcomes evaluated after RFM were myoma diameters (centimeters)
Time Frame
12 months
Title
Uterine Fibroid Symptom and Quality of Life (UFS-QOL) score after radiofrequency myolysis (RFM)
Description
Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire with scores ranging from 0 to 100, were higher QOL scores mean a better health-related QOL 1 and a 10-point scale used for each reported symptom.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Surgical time of radiofrequency myolysis (RFM)
Description
The surgical time (minutes) for each different type of surgical access
Time Frame
12 months
Title
Surgical time of radiofrequency myolysis (RFM) assisted by new technologies
Description
The reduction of surgical time (minutes) with the use of a virtual global positioning system (GPS) track system or a contrast-enhanced ultrasound during the ablation
Time Frame
12 months
Title
Pre-intervention biopsy associated to radiofrequency myolysis (RFM)
Description
The number of biopsies for treated fibroma
Time Frame
12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
62 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
"Inclusion Criteria": women who had symptomatic myomas with diameters ranging between 1.2 and 7.7 cm. - patients who had declined hysterectomy or laparoscopic myomectomy submucosal fibroids with intramural extension ≥50% intramural fibroids (FIGO G3 / G4 types) subserosal fibroids (FIGO G5 / G6 types) "Exclusion Criteria": Women with intracavitary (FIGO G0 / G1 types) or subserosal-pedunculated fibroids / (FIGO G7 types) genital malignancy cervical dysplasias pelvic infection / adhesions severe systemic diseases pregnancy deeply infiltrating endometriosis patients who took gonadotropin-releasing hormone therapy or acetate ulipristal within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alessandro FASCIANI
Organizational Affiliation
International Evangelical Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
International Evangelical Hospital
City
Genoa
ZIP/Postal Code
16125
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29750955
Citation
Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP, Nicholson WK, Anchan RM, Venable S, Wallace K, Marsh EE, Maxwell GL, Borah BJ, Catherino WH, Myers ER. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. Am J Obstet Gynecol. 2018 Jul;219(1):95.e1-95.e10. doi: 10.1016/j.ajog.2018.05.004. Epub 2018 May 8.
Results Reference
background
PubMed Identifier
28357157
Citation
Toub DB. A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System. Curr Obstet Gynecol Rep. 2017;6(1):67-73. doi: 10.1007/s13669-017-0194-2. Epub 2017 Feb 15.
Results Reference
background
PubMed Identifier
25355802
Citation
Yin G, Chen M, Yang S, Li J, Zhu T, Zhao X. Treatment of uterine myomas by radiofrequency thermal ablation: a 10-year retrospective cohort study. Reprod Sci. 2015 May;22(5):609-14. doi: 10.1177/1933719114556481. Epub 2014 Oct 29.
Results Reference
background
PubMed Identifier
30253997
Citation
Lin L, Ma H, Wang J, Guan H, Yang M, Tong X, Zou Y. Quality of Life, Adverse Events, and Reintervention Outcomes after Laparoscopic Radiofrequency Ablation for Symptomatic Uterine Fibroids: A Meta-Analysis. J Minim Invasive Gynecol. 2019 Mar-Apr;26(3):409-416. doi: 10.1016/j.jmig.2018.09.772. Epub 2018 Sep 22.
Results Reference
background
PubMed Identifier
30012030
Citation
Turtulici G, Orlandi D, Dedone G, Mauri G, Fasciani A, Sirito R, Silvestri E. Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study. Int J Hyperthermia. 2019 Jan 1;35(1):97-104. doi: 10.1080/02656736.2018.1479778. Epub 2018 Jul 17.
Results Reference
result

Learn more about this trial

Tailored Radiofrequency Ablation of Uterine Myomas

We'll reach out to this number within 24 hrs